Genovis AB GENO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- SEK 27.85
- Day Range
- SEK 27.50–28.85
- 52-Week Range
- SEK 25.65–66.90
- Bid/Ask
- SEK 28.25 / SEK 28.55
- Market Cap
- SEK 1.87 Bil
- Volume/Avg
- 32,687 / 129,327
Key Statistics
- Price/Earnings (Normalized)
- 29.11
- Price/Sales
- 11.52
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Genovis AB provides enzymes and technologies for the analytical characterization and conjugation of biopharmaceuticals. The principal activities of the company are to develop, produce, and market tools for developing new drugs and diagnostics. Its product line comprises GingisREX, FabRICATOR, GlyCLICK, GingisKHAN, GlycINATOR, Fabulous, lgGZERO, and Enzymes for O-glycan. The company's main product category consists of Enzymes and Antibodies. Geographically its segments include Sweden and the rest of the world.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 37
- Website
- https://www.genovis.com
Comparables
Valuation
|
Metric
|
GENO
|
ULTI
|
BICO
|
|---|---|---|---|
Price/Earnings (Normalized) | 29.11 | — | — |
Price/Book Value | 9.56 | 0.86 | 0.67 |
Price/Sales | 11.52 | — | 1.50 |
Price/Cash Flow | 28.32 | — | — |
Price/Earnings
GENO
ULTI
BICO
Financial Strength
|
Metric
|
GENO
|
ULTI
|
BICO
|
|---|---|---|---|
Quick Ratio | 6.79 | 4.82 | 1.76 |
Current Ratio | 7.49 | 4.85 | 2.41 |
Interest Coverage | 23.95 | — | −16.51 |
Quick Ratio
GENO
ULTI
BICO
Profitability
|
Metric
|
GENO
|
ULTI
|
BICO
|
|---|---|---|---|
Return on Assets (Normalized) | 26.91% | −43.08% | −4.22% |
Return on Equity (Normalized) | 35.49% | −50.37% | −6.38% |
Return on Invested Capital (Normalized) | 31.99% | −53.50% | −4.08% |
Return on Assets
GENO
ULTI
BICO
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Sqsdrrlf | Bxz | $572.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Cllrtlm | Wpkdgk | $103.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hyxfgxr | Hzwbqq | $99.6 Bil | |
MRNA
| Moderna Inc | Srplkfdy | Zbhr | $42.7 Bil | |
ARGX
| argenx SE ADR | Ffxfjxszl | Fmnx | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Vfxkrpzlv | Xlmc | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xdmngshmv | Lpkpxp | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vbnfynyc | Jrtscn | $15.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Smmdhqtjgl | Fdtbdkt | $12.7 Bil | |
INCY
| Incyte Corp | Fmtzhftv | Gwsdpv | $11.9 Bil |